Aerami
is a North Carolina-based biopharmaceutical company that researches and develops inhaled therapies for the treatment of cardiopulmonary diseases... Read moreAerami
is a North Carolina-based biopharmaceutical company that researches and develops inhaled therapies for the treatment of cardiopulmonary diseases... Read more
2010
PrivateMerger Pending with FoxWayne Enterprises Acquisition Corp
News
Sep 03, 2024
The Business Journals: Greensboro/Winston-Salem/High Point
Aerami: Durham firm raised $80 million. Now the company is gone.
May 20, 2024
StreetInsider
Press Release: Aerami : Aerami Therapeutics Presents New Lung Deposition Modeling Data For AER-901 in Pulmonary Hypertension at the American Thoracic Society 2024 International Conference
May 08, 2024
Benzinga
Aerami: Aerami Therapeutics to Present New Lung Deposition Modeling Data for AER-901, in Development for Pulmonary Hypertension, at the American Thoracic Society 2024 International Conference
Nov 29, 2023
The Business Journals
Aerami: Aerami Therapeutics raises capital to advance PHT treatment
Oct 05, 2023
GlobeNewswire
Press Release: Aerami : Aerami Therapeutics to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023
Sep 12, 2023
GlobalNewswire
Press Release: Aerami : Aerami Therapeutics Announces Presentation of Phase 1 Clinical Trial Data for Lead Program AER-901 at the 2023 European Respiratory Society (ERS) International Congress
Jun 02, 2023
Contract Pharma
Aerami: Aerami Therapeutics Expands Management Team
Jun 02, 2023
OINDPnews
Aerami: Aerami Therapeutics announces appointment of interim CEO and additional management positions
Jun 02, 2023
The Business Journals
Aerami: Durham firm names new leadership after CEO's death
May 25, 2023
OINDPnews
Aerami: Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD
Aerami Competitors
1
2
3
4
5
6
7
8
9
10